Naila Meese

Associate

Atlanta + 1.404.581.8266

Connect:

Share

Naila Meese advises public companies on transactions and issues related to capital markets, federal securities law, and Securities & Exchange Commission (SEC) periodic reporting obligations, including periodic filings, proxy statements, and Section 16 matters. She also represents companies in public and private offerings of equity and debt securities. Her experience includes registered offerings, take-private transactions, special purpose acquisition company "de-SPAC" transactions, and other capital markets transactions.

Naila has represented companies across a range of industries, including enterprise software, critical metals and minerals, and pharmacy services.

Experience

  • Guardian Pharmacy Services completes $181 million follow-on public offering, including “synthetic secondary” transactionJones Day represented Guardian Pharmacy Services, Inc. (NYSE: GRDN), a leading long-term care pharmacy services company, in connection with its $181 million underwritten follow-on public offering.
  • Logility enters into acquisition agreement with ApteanJones Day advised Logility Supply Chain Solutions, Inc. (NASDAQ: LGTY) in the acquisition by Aptean, Inc., a private equity-backed enterprise software company, for $14.30 per share in cash, or an enterprise value of approximately $490 million.
  • Molex acquires AirBornJones Day is advising Molex, a leading global connectivity and electronics solutions provider, in the acquisition of AirBorn, Inc., a company specializing in the design and manufacturing of rugged connectors and electronic components for global Original Equipment Manufacturers (OEMs) serving the aerospace and defense, commercial air, space exploration, medical, and industrial markets.
    • View All

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.